{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T01:56:16Z","timestamp":1771725376093,"version":"3.50.1"},"reference-count":32,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2019,11,30]]},"DOI":"10.5582\/irdr.2019.01121","type":"journal-article","created":{"date-parts":[[2020,1,11]],"date-time":"2020-01-11T22:03:52Z","timestamp":1578780232000},"page":"231-238","source":"Crossref","is-referenced-by-count":15,"title":["Quality of life in refractory generalized myasthenia gravis: A rapid review of the literature"],"prefix":"10.5582","volume":"8","author":[{"given":"Nathaly","family":"Garz\u00f3n-Orjuela","sequence":"first","affiliation":[{"name":"Department of Evidence-Based Medicine, NeuroEconomix, Bogot\u00e1, Colombia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"van der Werf","sequence":"additional","affiliation":[{"name":"Department of Evidence-Based Medicine, NeuroEconomix, Bogot\u00e1, Colombia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Catalina","family":"Prieto-Pinto","sequence":"additional","affiliation":[{"name":"Department of Evidence-Based Medicine, NeuroEconomix, Bogot\u00e1, Colombia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieralessandro","family":"Lasalvia","sequence":"additional","affiliation":[{"name":"Department of Evidence-Based Medicine, NeuroEconomix, Bogot\u00e1, Colombia."},{"name":"Clinical Epidemiology and Biostatistics Department, Medical School, Pontificia Universidad Javeriana, Bogot\u00e1, Colombia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilo","family":"Casta\u00f1eda-Cardona","sequence":"additional","affiliation":[{"name":"Department of Evidence-Based Medicine, NeuroEconomix, Bogot\u00e1, Colombia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Rosselli","sequence":"additional","affiliation":[{"name":"Department of Evidence-Based Medicine, NeuroEconomix, Bogot\u00e1, Colombia."},{"name":"Clinical Epidemiology and Biostatistics Department, Medical School, Pontificia Universidad Javeriana, Bogot\u00e1, Colombia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Gilhus NE. Myasthenia and the neuromuscular junction. Curr Opin Neurol. 2012; 25:523-529.","DOI":"10.1097\/WCO.0b013e3283572588"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016; 375:2570-2581.","DOI":"10.1056\/NEJMra1602678"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010; 10:46.","DOI":"10.1186\/1471-2377-10-46"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Silvestri NJ, Wolfe GI. Myasthenia gravis. Semin Neurol. 2012; 32:215-226.","DOI":"10.1055\/s-0032-1329200"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Luchanok V, Kaminski HJ. Natural History of Myasthenia Gravis. Engel A, ed. 2012; pp. 90-107.","DOI":"10.1093\/med\/9780199738670.003.0004"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve. 2004; 29:484-505.","DOI":"10.1002\/mus.20030"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019; 5:30.","DOI":"10.1038\/s41572-019-0079-y"},{"key":"8","unstructured":"8. Ropper AH, Samuels MA, Klein JP. Chapter 49. Myasthenia Gravis and Related Disorders of the Neuromuscular Junction. The McGraw-Hill Companies, New York, 2014."},{"key":"9","doi-asserted-by":"crossref","unstructured":"10. Boldingh MI, Dekker L, Maniaol AH, Brunborg C, Lipka AF, Niks EH, Verschuuren JJ, Tallaksen CM. An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts. Health Qual Life Outcomes. 2015; 13:115.","DOI":"10.1186\/s12955-015-0298-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"11. Fregonezi GA, Regiane-Resqueti V, Pradas J, Vigil L, Casan P. The relationship between lung function and health-related quality of life in patients with generalized myasthenia gravis. Arch Bronconeumol. 2006; 42:218-224. (in Spanish)","DOI":"10.1016\/S1579-2129(06)60449-7"},{"key":"11","doi-asserted-by":"crossref","unstructured":"12. Paul RH, Nash JM, Cohen RA, Gilchrist JM, Goldstein JM. Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve. 2001; 24:512-516.","DOI":"10.1002\/mus.1034"},{"key":"12","doi-asserted-by":"crossref","unstructured":"13. Yang Y, Zhang M, Guo J, Ma S, Fan L, Wang X, Li C, Guo P, Wang J, Li H, Li Z. Quality of life in 188 patients with myasthenia gravis in China. Int J Neurosci. 2016; 126:455-462.","DOI":"10.3109\/00207454.2015.1038712"},{"key":"13","doi-asserted-by":"crossref","unstructured":"14. Hern\u00e1ndez E, Aguirre MEE, Blanco TA, Pascual IJ. Myasthenia gravis: Sleep quality, quality of life, and disease severity. Muscle Nerve. 2012; 46:174-180.","DOI":"10.1002\/mus.23296"},{"key":"14","doi-asserted-by":"crossref","unstructured":"15. Hoffmann S, Ramm J, Grittner U, Kohler S, Siedler J, Meisel A. Fatigue in myasthenia gravis: Risk factors and impact on quality of life. Brain Behav. 2016; 6:e00538.","DOI":"10.1002\/brb3.538"},{"key":"15","doi-asserted-by":"crossref","unstructured":"16. Kumar R, Nagappa M, Sinha S, Taly A, Rao S. MG-QoL-15 scores in treated myasthenia gravis: Experience from a university hospital in India. Neurol India. 2016; 64:405-410.","DOI":"10.4103\/0028-3886.181542"},{"key":"16","doi-asserted-by":"crossref","unstructured":"17. Cioncoloni D, Casali S, Ginanneschi F, Carone M, Veronica B, Rossi A, Giannini F. Major motor-functional determinants associated with poor self-reported health-related quality of life in myasthenia gravis patients. Neurol Sci. 2016; 37:717-723.","DOI":"10.1007\/s10072-016-2556-3"},{"key":"17","doi-asserted-by":"crossref","unstructured":"18. Cohen RA, Moser DJ, Clark MM, Aloia MS, Cargill BR, Stefanik S, Albrecht A, Tilkemeier P, Forman DE. Neurocognitive functioning and improvement in quality of life following participation in cardiac rehabilitation. Am J Cardiol. 1999; 83:1374-1378.","DOI":"10.1016\/S0002-9149(99)00103-4"},{"key":"18","doi-asserted-by":"crossref","unstructured":"20. Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O&apos;Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017; 16:976-986.","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"19","doi-asserted-by":"crossref","unstructured":"21. Andersen H, Mantegazza R, Wang JJ, O&apos;Brien F, Patra K, Howard JF Jr; REGAIN Study Group. Eculizumab improves fatigue in refractory generalized myasthenia gravis. Qual Life Res. 2019; 28:2247-2254.","DOI":"10.1007\/s11136-019-02148-2"},{"key":"20","doi-asserted-by":"crossref","unstructured":"22. Muppidi S, Utsugisawa K, Benatar M, <i>et al<\/i>. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019; 60:14-24.","DOI":"10.1002\/mus.26447"},{"key":"21","doi-asserted-by":"crossref","unstructured":"23. Oosterhuis HJ. The natural course of myasthenia gravis: A long term follow up study. J Neurol Neurosurg Psychiatry. 1989; 52:1121-1127.","DOI":"10.1136\/jnnp.52.10.1121"},{"key":"22","doi-asserted-by":"crossref","unstructured":"24. Jeong A, Min JH, Kang YK, Kim J, Choi M, Seok JM, Kim BJ. Factors associated with quality of life of people with myasthenia gravis. PLoS One. 2018; 13:e0206754.","DOI":"10.1371\/journal.pone.0206754"},{"key":"23","unstructured":"25. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000; 55:16-23."},{"key":"24","doi-asserted-by":"crossref","unstructured":"26. Jones SM, Gwathmey K, Burns TM. Quality of life measures for myasthenia gravis and evaluation of non-motor symptoms. Clin Exp Neuroimmunol. 2015; 6:32-39.","DOI":"10.1111\/cen3.12174"},{"key":"25","doi-asserted-by":"crossref","unstructured":"27. Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol. 2014; 175:408-418.","DOI":"10.1111\/cei.12217"},{"key":"26","doi-asserted-by":"crossref","unstructured":"28. Silvestri NJ, Wolfe GI. Treatment-Refractory Myasthenia Gravis. J Clin Neuromuscul Dis. 2014; 15:167-178.","DOI":"10.1097\/CND.0000000000000034"},{"key":"27","doi-asserted-by":"crossref","unstructured":"29. Dhillon S. Eculizumab: A review in generalized myasthenia gravis. Drugs. 2018; 78:367-376.","DOI":"10.1007\/s40265-018-0875-9"},{"key":"28","doi-asserted-by":"crossref","unstructured":"30. Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019; 12:1756286419832242.","DOI":"10.1177\/1756286419832242"},{"key":"29","unstructured":"31. Alexion Pharmaceuticals I. Soliris (eculizumab): US prescribing information. 2017. <i>https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125166s172lbl.pdf <\/i>(accessed July 10, 2019)"},{"key":"30","unstructured":"32. Alexion Europe SAS. Soliris (eculizumab): summary of product characteristics. 2017. <i>https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/soliris-epar-product-information_en.pdf<\/i> (accessed July 10, 2019)"},{"key":"31","unstructured":"33. Alexion Pharmaceuticals, Inc. Soliris\u00ae (Eculizumab) Receives Marketing Authorization In Japan For The Treatment Of Patients With Generalized Myasthenia Gravis (GMG). 2007. <i>https:\/\/news.alexion.com\/press-release\/product-news\/soliris-eculizumab-receives-marketing-authorization-japan-treatment-patie<\/i> (accessed July 10, 2019)"},{"key":"32","doi-asserted-by":"crossref","unstructured":"34. Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, Melms A, Tackenberg B, Schalke B, Schneider-Gold C, Zimprich F, Meuth SG, Wiendl H. Clinical features, pathogenesis, and treatment of myasthenia gravis: A supplement to the Guidelines of the German Neurological Society. J Neurol. 2016; 263:1473-1494.","DOI":"10.1007\/s00415-016-8045-z"}],"container-title":["Intractable &amp; Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/8\/4\/8_2019.01121\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,18]],"date-time":"2020-01-18T03:35:52Z","timestamp":1579318552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/8\/4\/8_2019.01121\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,30]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2019.01121","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,30]]}}}